SIPE	
10, 2	
APR 1 2 2004	[نو
Please type	and sign (+) lesside this box →
TO A TO A DESCRIPTION	sperwork Reduction Act of 1995, no persons are
1040	Coloria de fera ferma 144

PTO/SB/DBA (10-	88
Approved for use through 19/31/99. QMG 0551-00	31
Patent and Trademark Office: U.S. DEPARTMENT OF COMMER	Œ

	Substitute fo	or form 14	19A/PTO	Co	Complete if Known				
	STAT	EMENT	N DISCLOSURE BY APPLICANT heets as necessary)	Application Number	10/751,056				
	•		•	Filing Date	January 2, 2004				
				First Named Inventor	Gerianne Tringali DiPiano				
l				Group Art Unit	1617				
				Examiner Name	J. Kim				
Sheet	1	of	2	Attorney Docket Number	FEM 104				

xaminer's	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
Initials No.		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
ν		FENTIMAN, et al., "Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial," Br J Surg., 75(9): 845-846 (1988).						
1		FENTIMAN, et al., "Studies of temoxifen in women with mastalgia," <i>Br. J. Cönical Prac. Sympt.</i> 68: 34-36 (1989).						
		HINTON, et al., "A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain," <i>Br. J. Clin. Practice</i> 40(8): 326-330 (1986).						
		HOLLAND & GATELEY, "Orug therapy of mastalgia. What are the options?" Drugs 48(5): 709-716 (1994).						
	******	IRVIN & MORRISON, "Effectiveness of topical non-steroidal anti-inflammatory drugs in the management of breast pain," J. R. Coll. Edinb. 43(3): 158-159 (1998).						
		LEONARD, et al., "Randomized, double-blind, placebo-controlled, multicenter trial of 6% milterosine solution, a topical chemotherapy in cutaneous matastases from breast cancer," J. Clin. Oncol. 19: 4150-4159 (2001).						
		MANSEL & DOGLIOTTI, "European multicentre trial of bromocriptine in cyclical mastelgia," Lancet 335(868): 190-193 (1990).						
		MANSEL, et al., "A double blind trial of the protectin inhibitor bromocriptine in painful benign breast disease," Br. J. Surgery 65(10): 724-27 (1978).						
	-	MANSEL, et al., "Controlled trial of the antigonadotropia danazol in painful nodular benign breast disease," Lancer 1(8278): 928-933 (1982).						
1		MILLET & DIRBAS, "Clinical management of breast pain: a review," Obstet. Gynecol. Survey 57(7): 451-461 (2002).						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Signature

¹ Unique citation designation number ¹ See attached Kinds of U.S. Patent Documents: ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

OIPE	
()	
APR 1 2 2004 \$\frac{1}{2}\] Pleases type o phylodo (-) baside this bax ->	<u> </u>
REAL MARKET	
TRADE And Proper work Reduction Act of 1885, co	persons are required to respon

PTO/SBOSA (10-68 Approved for use through 10/31/99, CAUS 0651-0031 Petent and Trademark Officia: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		9A/PTO	Complete if Known			
	STATE	MENT	N DISCLOSURE BY APPLICANT	Application Number	10/751,056	
			,,	Filling Date	January 2, 2004	
				First Named Inventor	Gerianne Tringali DiPiano	
				Group Art Unit		
				Examiner Name		
		of		Attorney Docket Number	FEM 104	

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journel, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
V		NAZLI, et al., "Controlled trial of the prolectin inhibitor bromocriptine (Parkedel) in the treatment of severe cyclical mastelgia," Br J Clin Pract 43: 322-327 (1989).	
1		STEINBRUNN, et al., "Mastelgia. Teiloring treatment to type of breast pain," Postgraduate Medicina 102(5): 183-184; 187-187; 193-194 (1997).	
		TERWOGT, et al., "Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer," Br. J. Cancer 79: 1158-1161 (1999).	
7/		UNGER, et al., "Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients," Concer Treat. Rev. 17: 243-246 (1990).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

	•	ı
•	٩	۰

				L	Paleni an	I TIBOSTICIA OTICO. U.S. DEFANTMENT OF COMMENCE
	Under the Pa	sperwork Reduct	tion Act of 1995, a	no persons are required to respond to a collec	tion of information unless it contains a valid OMB	control number
		Substitute f	or form 1449	APTO	Con	plete if Known
6	PE	کن اللہ کتا	ATEME	TION DISCLOSURE NT BY APPLICANT ny sheets as necessary)	Application Number	10/751,058
į Pi	16 2 1 6	Æ;			Filing Date	January 2, 2004
12.	1	æ/			First Named Inventor	Gerlanne DiPiano
1	ZE TRAE	EMA			Group Art Unit	1614
. `	C THAT				Examiner Name	
	Sheet	1	of	1	Attorney Docket Number	FEM 104

			U.S. PATENT DOCUM	ENTS	
Examiner Cite No.1		US Patent Document	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Kind Code ² (if known)				
7/		2004/0138314	Bua	07-15-2004	
-			*		
				 	

				F	OREIGN PATENT DOCUMEN	TS	· · · · · · · · · · · · · · · · · · ·	
Examiner Cite Initials* No.	Cite No.1					Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ja
		Office.3	Number ^a	Kind Code ⁵ (if known)			r iguius Appeal	
								 -
						 	······································	
			· · · · · · · · · · · · · · · · · · ·					
								
								·
Examiner's Signature					, Da	te Considered	3/30/07	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

F . .

2210 jype a plus sign (+) ist	ide (bis bon →							Palesta	PTO/SAGU Approved foruse through 1071/59, CMB 05 Taxlemark Office: U.S. DEPARTMENT OF COM	31-0031
nder das Papermark Reducti Sulbstitu	e Act of 1995, no pe te for form 14	traces are required 449A/PTO	io respond to a collection of in	damalion univers	t consider a roll OMB o	onkral man		plete i	/ Known	
			DISCLOSUI Y APPLICAI		Application N	umbe		-	10751,058	
	(use 89	many shee	els as necessary)		Filing Date				January 2, 2004	
					First Named I Group Art Un	it	or		Gerianne Tringali DiPlano 1617	
heat 1	of	· —	1		Examiner Na Attorney Doc		mber		PCIM, Jennifer M PEM 104	
				TIC DATE	NT DOCUME	213			····	
Examiner Cite US Patent Document Initials* No.		Document Kind Code 4		atantee or Aş led Documer	plicant	D	ite of Citled locument I-DD-YYYY	Pe	ges, Columns, Lines, Where Relevan assages or Relevant Figures Appear	n k
(if known)						44 40	-1991			
7	5,066,495 6,482,448		Moro, et al. Tabor				-2002			
									······································	
						-				
						-				
										_
										
			F	OREIGN P	ATENT DOCU	MENT	9			—
Examiner Cite No.	Fo	reign Patent		Nam	e of Palentes or it of Cited Docum		Date of Publica Cited Documer OD-YYYY	MM-	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7"
	Office."	Number	iGnd Code ^b (if known)				-			↓_
										+
										F
				 		_				土
										+
										F
					_					二
	•					16-	n Complete and			
Examiner's Signature				> ,		Da	e Considered		3/30/01	
*EXAMINER: Initi	el II refarence s form with ne	considered, y	whether or not citation ation to application.	is in confor	nance with MPEF	609.	Draw line throu	gh citat	ion if not in conformance and not con	aidere

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-latter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the relign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the exprepriate symbols as indicated on the document under WIPO Standard ST. 16 8 possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any commants on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

and the control of th

AND THE RESERVE OF THE PROPERTY OF THE PROPERT

45081024v1

FEM 104 077049/00010